Back to top
more

VERADIGM INC (MDRX)

(Delayed Data from OTC)

$9.01 USD

9.01
41,502

-0.47 (-4.96%)

Updated Jun 14, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 250)

Industry: Technology Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is AllScripts (MDRX) Down 17.1% Since Last Earnings Report?

by Zacks Equity Research

AllScripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Computer Systems & Jasper General Tie Up to Boost EHR Service

by Zacks Equity Research

Computer Systems (CPSI) sees a series of developments in the EHR platform.

Allscripts Partners With Opargo to Boost Practice Management

by Zacks Equity Research

Allscripts' (MDRX) partnership with Opargo is likely to improve scheduling capabilities and practice workflows of Allscripts Practice Management solution.

Allscripts Strengthens Strategic Relationship with Pulse8

by Zacks Equity Research

Pulse8 is likely to boost Allscripts' (MDRX) flagship platform Veradigm, and its existing health plan product suite that delivers pocket-friendly tools and services for health plan members.

Allscripts to Fortify Middle East Foothold With New Project

by Zacks Equity Research

Qatar-based Alfardan Group and Chicago-based Northwestern Medicine select Allscripts (MDRX) for the launch of a project in the Middle East.

Allscripts (MDRX) Q4 Earnings Lag Estimates, Bookings Up Y/Y

by Zacks Equity Research

Significant year-over-year rise in bookings favors Allscripts' (MDRX) fourth-quarter 2018 results.

AllScripts Healthcare (MDRX) Misses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

AllScripts (MDRX) delivered earnings and revenue surprises of -4.76% and -4.53%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

AllScripts Healthcare (MDRX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Allscripts (MDRX) Down 15.2% Since Last Earnings Report: Can It Rebound? (Revised)

by Zacks Equity Research

AllScripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allscripts (MDRX) Misses Q3 Earnings and Revenue Estimates (Revised)

by Zacks Equity Research

Allscripts (MDRX) witnessed solid growth in Software delivery, Support and Maintenance and Client services segments in Q3.

Allscripts Selected by Premier for Connected Health Platform

by Zacks Equity Research

Premier Orthopaedics will leverage on Allscripts' (MDRX) Professional EHR, Practice Management software, FollowMyHealth and Payerpath suite of solutions.

Cerner (CERN) Teams Up With Nebraska-Based LRHC, Shares Up

by Zacks Equity Research

Cerner's (CERN) coveted Millennium platform has seen rising demand in recent times.

Allscripts (MDRX) Collaborates With Microsoft, Shares Up

by Zacks Equity Research

Allscripts' (MDRX) Veradigm unit signs a memorandum of understanding with Microsoft to develop an integrated research model.

Allscripts Healthcare (MDRX) Catches Eye: Stock Jumps 5.7%

by Zacks Equity Research

Allscripts Healthcare (MDRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Here's Why You Should Hold Allscripts Stock in Your Portfolio

by Zacks Equity Research

Allscripts (MDRX) has been winning contracts in the Sunrise EHR platform; competition stiff.

AllScripts (MDRX) Down 15.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

AllScripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allscripts Healthcare Solutions (MDRX): Moving Average Crossover Alert

by Zacks Equity Research

Allscripts Healthcare Solutions, Inc. (MDRX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Allscripts (MDRX) Misses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Significant margin contraction hurts Allscripts' (MDRX) results in Q3; decline in bookings discourages.

AllScripts Healthcare (MDRX) Q3 Earnings and Revenues Lag Estimates

by Zacks Equity Research

AllScripts (MDRX) delivered earnings and revenue surprises of -5.26% and -1.85%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

AllScripts Healthcare (MDRX) Q3 Earnings Preview: What to Expect

by Zacks Equity Research

AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Veeva Launches Vault SiteDocs for Regulatory Documentation

by Zacks Equity Research

Veeva's (VEEV) Vault SiteDocs Platform conducts high-quality, compliant clinical trials with greater visibility to researchers.

    Cerner's Millennium Platform Integrated at McLaren Hospital

    by Zacks Equity Research

    Cerner's (CERN) Millennium HCIT platform sees a series of developments in 2018.

    Here's Why You Should Hold on to athenahealth (ATHN) for Now

    by Zacks Equity Research

    athenahealth (ATHN) likely to gain from focus on cloud-based healthcare services.

    Allscripts (MDRX) & Appriss Health Collaborate to Fight SUD

    by Zacks Equity Research

    Allscripts' (MDRX) EHR solutions have lucrative prospects.

    Here's Why You Should Hold on to Cerner (CERN) Stock for Now

    by Zacks Equity Research

    Cerner (CERN) likely to gain from focus on big-data based healthcare services.